Lilly buys migraine antibody

Share this article:

Eli Lilly announced Monday that it scooped up rights for an antibody that Phase-II data indicate may help treat recurrent migraine headaches.

Lilly had in fact discovered the molecule, LY2951742, which is a calcitonin gene-related peptide antibody, but licensed development to Arteaus Therapeutics. The development deal was an alternative risk-sharing strategy: Atlas Venture and Orbimed created Arteaus in 2011 once the antibody license was in place.

Eli Lilly said it expects Monday's deal will trigger a $57.1 million pre-tax fourth-quarter charge.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.